Disclosed herein are new compositions comprising a purified cannabinoid and a purified terpene. In one embodiment, the compositions comprise one or more purified cannabinoids. In one embodiment, the compositions comprise one or more purified cannabinoids in combination with one or more purified terpenes. In one embodiment, the compositions comprise unnaturally occurring ratios. In one embodiment, the compositions comprise unnaturally occurring concentrations. In one embodiment, the compositions comprise unexpected and/or synergistic effects.

Disclosed is a method of treating a subject having non-small cell lung cancer. The method includes administering to the subject a therapeutically effective amount of a composition and the composition contains 5-demethylnobiletin and docetaxel. Compared with the use of docetaxel alone, the method of combining 5-demethylnobiletin and docetaxel had a 4.4 fold increase in inhibiting the growth of human lung cancer cells, and had a 3.05 fold increase in inhibiting tumor growth in human lung cancer cell-engrafted nude mice.

Disclosed is a method of treating a subject having non-small cell lung cancer. The method includes administering to the subject a therapeutically effective amount of a composition and the composition contains 5-demethylnobiletin and docetaxel. Compared with the use of docetaxel alone, the method of combining 5-demethylnobiletin and docetaxel had a 4.4 fold increase in inhibiting the growth of human lung cancer cells, and had a 3.05 fold increase in inhibiting tumor growth in human lung cancer cell-engrafted nude mice.

The present invention concerns compounds of formula (I), enantiomers, mixture of enantiomers, diastereoisomers and mixture of diasteroisomers thereof formula (I): wherein at least one of W, X and Y is selected from the group consisting of —NR.sub.1R.sub.2; —NR.sub.3—(CH.sub.2).sub.n—NR.sub.4R.sub.5; —O—(CH.sub.2).sub.n—NR.sub.4R.sub.5; —NR.sub.3—(CH.sub.2).sub.n—N′R.sub.6R.sub.7R.sub.8; and —O—(CH.sub.2).sub.n—N′R.sub.6R.sub.7R.sub.8 and Z is a functional group capable of chelating iron salts. The present invention also concerns the compounds of formula (I) for use as a drug, in particular, in the treatment of cancer and malaria.

##STR00001##

The present invention concerns compounds of formula (I), enantiomers, mixture of enantiomers, diastereoisomers and mixture of diasteroisomers thereof formula (I): wherein at least one of W, X and Y is selected from the group consisting of —NR.sub.1R.sub.2; —NR.sub.3—(CH.sub.2).sub.n—NR.sub.4R.sub.5; —O—(CH.sub.2).sub.n—NR.sub.4R.sub.5; —NR.sub.3—(CH.sub.2).sub.n—N′R.sub.6R.sub.7R.sub.8; and —O—(CH.sub.2).sub.n—N′R.sub.6R.sub.7R.sub.8 and Z is a functional group capable of chelating iron salts. The present invention also concerns the compounds of formula (I) for use as a drug, in particular, in the treatment of cancer and malaria.

##STR00001##

The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

Provided herein is a method for identifying compounds that inhibit cell growth or have cytotoxic activity against cancer cells, such as hematological cancer cells or ovarian cancer cells, in a subject. Further provided is a method for identifying one or more compounds that sensitize refractory cancer cells from a subject. Also provided are compositions and methods for treating cancer, including refractory cancer, such as refractory acute myeloid leukemia (AML) or ovarian cancer.

Provided herein is a method for identifying compounds that inhibit cell growth or have cytotoxic activity against cancer cells, such as hematological cancer cells or ovarian cancer cells, in a subject. Further provided is a method for identifying one or more compounds that sensitize refractory cancer cells from a subject. Also provided are compositions and methods for treating cancer, including refractory cancer, such as refractory acute myeloid leukemia (AML) or ovarian cancer.

This disclosure is directed, at least in part, to GPR40 agonists useful for the treatment of conditions or disorders involving the gut-brain axis. In some embodiments, the GPR40 agonists are gut-restricted compounds. In some embodiments, the GPR40 agonists are full agonists or partial agonists. In some embodiments, the condition or disorder is a metabolic disorder, such as diabetes, obesity, nonalcoholic steatohepatitis (NASH), or a nutritional disorder such as short bowel syndrome.